Public Health England will use the company's Victor EnLite instrument and EnLite Neonatal TREC kit at three of six sites to evaluate screening newborns for "Bubble Boy" disease.
The urine-based test, which was already available in several markets, does not require any specialized instrumentation and produces results in less than three minutes.
The company attributed its revenue shortfall to billing issues in the prenatal testing business and announced that CFO Bryan Riggsbee will be interim CEO.
CEO Prahlad Singh said the firm is developing a PCR- and antibody-based assay for the novel coronavirus 2019-nCoV and is working with the Chinese NMPA.
Natera discussed its cancer and transplant rejection testing businesses, while Exact Sciences explained how it will benefit from its Genomic Health acquisition.
The new firm will offer target enrichment assays for clinical NGS testing and develop library preparation kits for clinical tests on Illumina's sequencing platform.
Researchers at Baylor College of Medicine and Columbia University found that almost all blood samples from pregnant women tested contained several trophoblasts.
The company said it will use the proceeds to increase commercialization of its PreTRM test, a blood biomarker test to determine the risk of premature delivery.
The company processed more than 200,000 tests during the quarter, an increase of 20 percent compared to the 167,000 tests it processed in Q3 of last year.
The company also said that it has acquired Beijing-based food safety testing firm Meizheng Group. The deal is expected to expand PerkinElmer's food safety capabilities.
